Biontech SE
BNTX105.965USD
+3.945+3.87%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
25.43BCap. mercado
PérdidaP/E TTM
Más Datos de Biontech SE Compañía
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Información de la empresa
Código de la empresaBNTX
Nombre de la empresaBiontech SE
Fecha de salida a bolsaOct 10, 2019
Fundada en2019
Director ejecutivoProf. Ugur Sahin, M.D.
Número de empleados6772
Tipo de seguridadDepository Receipt
Fin del año fiscalOct 10
DirecciónAn der Goldgrube 12
CiudadMAINZ
Bolsa de valoresNASDAQ Global Select Consolidated
PaísGermany
Código postal55131
Teléfono4949613190840
Sitio Webhttps://www.biontech.com/
Código de la empresaBNTX
Fecha de salida a bolsaOct 10, 2019
Fundada en2019
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+1.69%
Mr. Ryan Richardson
Mr. Ryan Richardson
Chief Strategy Officer, Member of the Management Board
Chief Strategy Officer, Member of the Management Board
26.55K
+80.66%
Mr. Jens Holstein
Mr. Jens Holstein
Chief Financial Officer, Member of the Management Board
Chief Financial Officer, Member of the Management Board
1.62K
--
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
--
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Mr. Helmut Jeggle
Mr. Helmut Jeggle
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Dr. Oezlem Tuereci, M.D.
Dr. Oezlem Tuereci, M.D.
Chief Medical Office, Member of the Management Board
Chief Medical Office, Member of the Management Board
--
--
Ms. Baroness Nicola Blackwood
Ms. Baroness Nicola Blackwood
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+1.69%
Mr. Ryan Richardson
Mr. Ryan Richardson
Chief Strategy Officer, Member of the Management Board
Chief Strategy Officer, Member of the Management Board
26.55K
+80.66%
Mr. Jens Holstein
Mr. Jens Holstein
Chief Financial Officer, Member of the Management Board
Chief Financial Officer, Member of the Management Board
1.62K
--
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
--
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Desglose de ingresos
Divisa: EURHora de actualización: mié., 12 de mar
Divisa: EURHora de actualización: mié., 12 de mar
FY2019
FY2018
FY2017
Por negocioEUR
Nombre
Ganancia
Proporción
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
Sin datos
Por negocio
Por región
Por negocioEUR
Nombre
Ganancia
Proporción
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
Accionista
Hora de actualización: jue., 13 de mar
Hora de actualización: jue., 13 de mar
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
AT Impf GmbH
42.44%
Medine GmbH
16.85%
Baillie Gifford & Co.
3.43%
Fidelity Management & Research Company LLC
2.69%
Flossbach von Storch AG
1.84%
Other
32.76%
Estadísticas de accionistas
Accionista
Proporción
AT Impf GmbH
42.44%
Medine GmbH
16.85%
Baillie Gifford & Co.
3.43%
Fidelity Management & Research Company LLC
2.69%
Flossbach von Storch AG
1.84%
Other
32.76%
Tipo
Accionista
Proporción
Corporation
60.82%
Investment Advisor
15.74%
Investment Advisor/Hedge Fund
3.45%
Individual Investor
2.41%
Hedge Fund
0.93%
Sovereign Wealth Fund
0.75%
Research Firm
0.65%
Pension Fund
0.21%
Bank and Trust
0.18%
Other
14.86%
Participación institucional
Hora de actualización: dom., 19 de ene
Hora de actualización: dom., 19 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
822
205.15M
85.49%
+3.95M
2024Q4
869
205.33M
85.56%
+3.19M
2024Q3
843
197.46M
82.52%
-2.61M
2024Q2
819
194.42M
81.78%
-7.50M
2024Q1
835
193.57M
81.42%
-10.02M
2023Q4
897
193.24M
81.29%
-7.90M
2023Q3
920
192.71M
79.62%
-7.47M
2023Q2
940
195.49M
80.61%
-8.54M
2023Q1
953
197.88M
81.52%
-6.52M
2022Q4
937
198.79M
81.74%
-3.98M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
AT Impf GmbH
101.85M
42.44%
-636.54K
-0.62%
Dec 31, 2024
Medine GmbH
40.43M
16.85%
-7.37K
-0.02%
Dec 31, 2024
Baillie Gifford & Co.
8.22M
3.43%
-87.49K
-1.05%
Dec 31, 2024
Fidelity Management & Research Company LLC
6.45M
2.69%
+1.27M
+24.48%
Dec 31, 2024
Flossbach von Storch AG
4.41M
1.84%
+47.24K
+1.08%
Dec 31, 2024
PRIMECAP Management Company
4.30M
1.79%
-220.70K
-4.89%
Dec 31, 2024
Pfizer Inc
3.66M
1.52%
+3.66M
--
Dec 31, 2024
Sahin (Ugur MD)
2.77M
1.16%
+1.92M
+224.09%
Dec 31, 2024
Temasek Holdings Pte. Ltd.
1.81M
0.75%
--
--
Dec 31, 2024
Wolfgang (Jeggle Helmut)
1.43M
0.59%
-100.00K
-6.55%
Dec 31, 2024
Ver más
ETFs relacionados
Hora de actualización: dom., 6 de abr
Hora de actualización: dom., 6 de abr
Nombre
Proporción
Global X Genomics & Biotechnology ETF
4.75%
Langar Global HealthTech ETF
4.42%
iShares Genomics Immunology and Healthcare ETF
4.13%
First Trust NYSE Arca Biotechnology Index Fund
2.86%
Franklin Genomic Advancements ETF
2.33%
VanEck Biotech ETF
2.2%
Range Cancer Immunotherapy ETF
1.61%
Virtus LifeSci Biotech Products ETF
1.51%
iShares Biotechnology ETF
1.38%
First Trust International Equity Opportunities ETF
1.33%
Ver más
Global X Genomics & Biotechnology ETF
Proporción4.75%
Langar Global HealthTech ETF
Proporción4.42%
iShares Genomics Immunology and Healthcare ETF
Proporción4.13%
First Trust NYSE Arca Biotechnology Index Fund
Proporción2.86%
Franklin Genomic Advancements ETF
Proporción2.33%
VanEck Biotech ETF
Proporción2.2%
Range Cancer Immunotherapy ETF
Proporción1.61%
Virtus LifeSci Biotech Products ETF
Proporción1.51%
iShares Biotechnology ETF
Proporción1.38%
First Trust International Equity Opportunities ETF
Proporción1.33%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos